Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
GINA 2026 no longer endorses a SABA alone for asthma, yet albuterol labels still list only bronchospasm. Airsupra adds exacerbation risk reduction for adults.
Recalibrating the ACCEPT COPD exacerbation prediction tool with country-specific background risk substantially improved its ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
The Lancet Respiratory Medicine Commission on the present and future of chronic obstructive pulmonary disease (COPD) ...
Chronic obstructive pulmonary disease and cardiovascular diseases are among the leading chronic health burdens worldwide. They share key modifiable risk factors as well as overlapping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results